ARCHIVES

Drugs and Targets: Blincyto granted accelerated approval in R/R ALL

This article is from The Cancer Letter archive.

Vol. 40 No. 45 | December 5, 2014

Download PDF Visit The Full Archive

Related Articles

Phase III Regorafenib Trial Meets PFS Primary Endpoint

June 29, 2012

Congress Renews National Cancer Act, Including Most Key Amendments Sought By NCI And Allied

October 28, 1988

Texas (Galveston) Scores Nine Points Ahead Of RPMI In Organ Systems Competitio; NCAB To Decide Award

May 4, 1984

AOR And PRN, Two Largest Oncology Practice Management Firms, To Merge

December 18, 1998

Obituary: Ernst Wynder, 77, Linked Smoking, Cancer

July 23, 1999

In Brief: Increasing Survival Through Adjuvant Therapy Seen As Adding To Cost Of Care

October 24, 1975